<html>
<h1>Hepatitis C virus sequence report</h1>
<h2>Sequence EF407428</h2>
<h3>Phylogenetic classification</h3>
The sequence was identified as hepatitis C virus.
<table>
<tr>

<td><b>Genotype</b></td>
<td>1</td>
</tr>
<tr>

<td><b>Subtype</b></td>
<td>1a</td>
</tr>

<tr>
<td><b>Closest reference sequence</b></td>
<td>M62321</td>
</tr>

</table>

<h3>Resistance-associated sequence polymorphisms detected</h3>
<table>
<tr>
<td rowspan = "4">NS3</td>
<td rowspan = "4">80K</td>
<td>glecaprevir</td>
<td>Krishnan et al., 2017</td>
</tr>
<tr>
<td>voxilaprevir</td>
<td>Wyles, et al., 2017</td>
</tr>
<tr>
<td>voxilaprevir</td>
<td>Dvory-Sobol et al., 2017</td>
</tr>
<tr>
<td>voxilaprevir</td>
<td>Sarrazin et al., 2017</td>
</tr>
<tr>
<td rowspan = "1">NS3</td>
<td rowspan = "1">168D</td>
<td>voxilaprevir</td>
<td>Wyles, et al., 2017</td>
</tr>
<tr>
<td rowspan = "1">NS5A</td>
<td rowspan = "1">30H</td>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td rowspan = "3">NS5A</td>
<td rowspan = "3">30H+93H</td>
<td>pibrentasvir</td>
<td>Poordad et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Curry et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td rowspan = "31">NS5A</td>
<td rowspan = "31">93H</td>
<td>pibrentasvir</td>
<td>Ng et al., 2017</td>
</tr>
<tr>
<td>pibrentasvir</td>
<td>Krishnan et al., 2017</td>
</tr>
<tr>
<td>pibrentasvir</td>
<td>Poordad et al., 2018</td>
</tr>
<tr>
<td>pibrentasvir</td>
<td>Ng et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Cheng et al., 2013</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gane et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gane et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Curry et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Curry et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Curry et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Curry et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gottwein et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Cheng et al., 2013</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gottwein et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gottwein et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Gottwein et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Lawitz et al., 2016</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Hezode et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Hezode et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Hezode et al., 2018</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Foster et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Foster et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Foster et al., 2015</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Bourlière et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Bourlière et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Bourlière et al., 2017</td>
</tr>
<tr>
<td>velpatasvir</td>
<td>Bourlière et al., 2017</td>
</tr>
</table>



<h2>References</h2>

<p>
[Curry et al., 2015] 
<b>Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.</b>
Curry MP, O&#39;Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS Jr, Charlton M, 
N. Engl. J. Med.
	373(27),
	2618-28
(2015)
<br/>
<a href="https://doi.org/10.1056/NEJMoa1512614">https://doi.org/10.1056/NEJMoa1512614</a> 
</p>
<p>
[Foster et al., 2015] 
<b>Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.</b>
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNally J, Osinusi A, Brainard DM, McHutchison JG, Mazzotta F, Tran TT, Gordon SC, Patel K, Reau N, Mangia A, Sulkowski M, 
N. Engl. J. Med.
	373(27),
	2608-17
(2015)
<br/>
<a href="https://doi.org/10.1056/NEJMoa1512612">https://doi.org/10.1056/NEJMoa1512612</a> 
</p>
<p>
[Lawitz et al., 2016] 
<b>Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.</b>
Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller MD, Mo H, 
Antimicrob. Agents Chemother.
	60(9),
	5368-78
(2016)
<br/>
<a href="https://doi.org/10.1128/AAC.00763-16">https://doi.org/10.1128/AAC.00763-16</a> 
</p>
<p>
[Ng et al., 2017] 
<b>In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.</b>
Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, Reisch T, Lu L, Dekhtyar T, Irvin M, Tripathi R, Maring C, Randolph JT, Wagner R, Collins C, 
Antimicrob. Agents Chemother.
	61(5),
(2017)
<br/>
<a href="https://doi.org/10.1128/AAC.02558-16">https://doi.org/10.1128/AAC.02558-16</a> 
</p>
<p>
[Gane et al., 2017] 
<b>Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.</b>
Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, Hinestrosa F, Dvory-Sobol H, Huang KC, Osinusi A, McNally J, Brainard DM, McHutchison JG, Thompson AJ, Sulkowski MS, 
Hepatology
	66(4),
	1083-1089
(2017)
<br/>
<a href="https://doi.org/10.1002/hep.29256">https://doi.org/10.1002/hep.29256</a> 
</p>
<p>
[Bourlière et al., 2017] 
<b>Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.</b>
Bourlière M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, 
N. Engl. J. Med.
	376(22),
	2134-2146
(2017)
<br/>
<a href="https://doi.org/10.1056/NEJMoa1613512">https://doi.org/10.1056/NEJMoa1613512</a> 
</p>
<p>
[Poordad et al., 2018] 
<b>Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.</b>
Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ, 
Hepatology
	67(4),
	1253-1260
(2018)
<br/>
<a href="https://doi.org/10.1002/hep.29671">https://doi.org/10.1002/hep.29671</a> 
</p>
<p>
[Hezode et al., 2018] 
<b>Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.</b>
Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O&#39;Leary JG, Shafran SD, Zeuzem S, 
J. Hepatol.
	68(5),
	895-903
(2018)
<br/>
<a href="https://doi.org/10.1016/j.jhep.2017.11.032">https://doi.org/10.1016/j.jhep.2017.11.032</a> 
</p>
<p>
[Gottwein et al., 2018] 
<b>Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.</b>
Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J, 
Gastroenterology
	154(5),
	1435-1448
(2018)
<br/>
<a href="https://doi.org/10.1053/j.gastro.2017.12.015">https://doi.org/10.1053/j.gastro.2017.12.015</a> 
</p>
<p>
[Krishnan et al., 2017] 
<b>Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials</b>
P. Krishnan, G. Schnell, R. Tripathi, T. Ng, T. Reisch, J. Beyer, T. Dekhtyar, M. Irvin, W. Xie, L. Larsen, F. Mensa, T. Pilot-Matias and C. Collins, 
J. Hepatol.
	66(1),
	S500
(2017)
<br/>
<a href="https://doi.org/10.1016/S0168-8278(17)31399-5">https://doi.org/10.1016/S0168-8278(17)31399-5</a> 
</p>
<p>
[Wyles, et al., 2017] 
<b>No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies</b>
D. Wyles, A. Thompson, E. Lawitz, B. Willems, E.J. Gane, E. Svarovskaia, H. Dvory-Sobol, R. Martin, G. Camus, B.P. Doehle, L.M. Stamm, R.H. Hyland, D.M. Brainard, H.M. Mo, T. Asselah, I. Jacobson, G.R. Foster and S. Roberts, 
J. Hepatol.
	66(1),
	S303
(2017)
<br/>
<a href="https://doi.org/10.1016/S0168-8278(17)30924-8">https://doi.org/10.1016/S0168-8278(17)30924-8</a> 
</p>
<p>
[Dvory-Sobol et al., 2017] 
<b>Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and of Clinical Isolates from Direct Acting Antiviral-Experienced and-Naive Patients</b>
H. Dvory-Sobol, B. Han, J. Lu, B. Parhy, D. Hsieh, E. Zhou, M. Bourlière, I. Jacobson, L. M. Stamm, G. Camus, R. Martin, E. S. Svarovskaia and H. Mo, 
Hepatology
	66(S1),
	632A
(2017)
<br/>
<a href="https://doi.org/10.1002/hep.29501">https://doi.org/10.1002/hep.29501</a> 
</p>
<p>
[Sarrazin et al., 2017] 
<b>No impact of RASs on the high efficacy of SOF/VEL/VOX for 12 weeks in DAA-experienced patients: an integrated resistance analysis of the POLARIS-1 and POLARIS-4 studies</b>
C. Sarrazin, C.L. Cooper, M.P. Manns, R.K. Reddy, K. Kowdley, H. Dvory-Sobol, E. Svarovskia, R. Martin, B.P. Doehle, G. Camus, L.M. Stamm, R.H. Hyland, D.M. Brainard, H. Mo, S.C. Gordon, M. Bourlière, S. Zeuzem and S.L. Flamm, 
J. Hepatol.
	66(1),
	S299
(2017)
<br/>
<a href="https://doi.org/10.1016/S0168-8278(17)30915-7">https://doi.org/10.1016/S0168-8278(17)30915-7</a> 
</p>
<p>
[Cheng et al., 2013] 
<b>GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIER</b>
G. Cheng, M. Yu, B. Peng, Y.-J. Lee, A. Trejo-Martin, R. Gong, C. Bush, A. Worth, M. Nash, K. Chan, H. Yang, R. Beran, Y. Tian, J. Perry, J. Taylor, C. Yang, M. Paulson, W. Delaney and J.O. Link, 
J. Hepatol.
	58(Supplement 1),
	S484-S485
(2013)
<br/>
<a href="https://doi.org/10.1016/S0168-8278(13)61192-7">https://doi.org/10.1016/S0168-8278(13)61192-7</a> 
</p>
</html>